Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTER, STRATIFIED STUDY EVALUATING THE EFFICACY AND SAFETY OF REPEAT DOSES OF GSK3772847 COMPARED WITH PLACEBO IN PARTICIPANTS WITH MODERATELY SEVERE ASTHMA

Intervention/treatment:
GSK3772847
Medical condition:
ASTHMA
Protocol code:
207597
Control number:
208044
Status:
Closed
Approved:
August 29, 2017
Date Completed:
Trial phase:
Phase 2
For more information:
ClinicalTrials.gov - NCT03207243
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
GSK Response Center
Organization
GlaxoSmithKline
Phone:
866-435-7343
Sponsor
GLAXOSMITHKLINE INC

Locations

Alberta

GSK Investigational Site
Sherwood Park, Alberta, T8H 0N2

British Columbia

GSK Investigational Site
Vancouver, British Columbia, V5Z 1M9
GSK Investigational Site
Vancouver, British Columbia, V6Z 1Y6

Ontario

GSK Investigational Site
Hamilton, Ontario, L8N 3Z5
GSK Investigational Site
Ottawa, Ontario, K1G 6C6
GSK Investigational Site
Québec, Ontario, G1V 4G5

Quebec

GSK Investigational Site
Montreal, Quebec, H2X 3E4
GSK Investigational Site
Montreal, Quebec, H4A 3J1
GSK Investigational Site
Trois-Rivières, Quebec, G8T 7A1

Results

See the results from the trial NCT03207243. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?